Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
-
Ivermectin (IVM) (HB1958)
Description:α7 nicotinic acetylcholine receptor positive allosteric modulator. Activates GluCI/GlyCI chemogenetic channels. Shows antiviral activity.
Purity:>95%
-
Linezolid (HB4443)
Description:Inhibits protein synthesis in gram-positive bacteria. Antibiotic.
Purity:>98%
-
Loperamide hydrochloride (HB0385)
Description:Potent, selective µ-opioid receptor agonist
Purity:>99%
-
-
-
Mefloquine hydrochloride (HB9555)
Description:Cx36 and Cx50 gap channel blocker. Antimalarial, antischistosomal and antiviral.
Purity:>98%
-
-
Oseltamivir phosphate (HB7776)
Description:Antiviral compound. Influenza viral neuraminidase inhibitor.
Purity:>98%
-
Ouabain (HB1140)
Description:Selective Na+ / K+ ATPase inhibitor. Shows antiviral activity.
Purity:>98%
